Phenylephrine 5% eye drops
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Phenylephrine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Phenylephrine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Phenylephrine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Cataracts in adults: management (NG77)
Caesarean birth (NG192)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 7 · Randomised trials: 29 · 1989–2026
Showing the 50 most relevant studies, sorted by most relevant.
Anna Lee, W. N. Ngan Kee, T. Gin
Anesthesia & Analgesia, 2002
D. G. Thomas, S. Robson, N. Redfern, et al.
British journal of anaesthesia, 1996
A. Morelli, C. Ertmer, S. Rehberg, et al.
Critical Care, 2008
M. Vallejo, A. Attaallah, Osama M Elzamzamy, et al.
International journal of obstetric anesthesia, 2017
Hordofa TA, Ilala TT, Mengistu K
2026
BackgroundThere are pharmacological and non-pharmacological approaches to preventing spinal induced hypotension. In obstetrics, norepinephrine may be an alternative to phenylephrine because it better maintains cardiac output and heart rate. We conducted this systematic review and meta-analysis to identify neonatal outcomes and maternal haemodynamic effects.MethodsThe systematic review of literature searched was conducted through electronic databases such as PubMed, Cochrane Library, and Google Scholar from February 1 to May 30,2025. All of the articles included in the review and meta-analysis were randomised controlled trials, and the populations of the study were normal pregnancies that underwent caesarean section under spinal anesthesia.ResultsA 19 studies of randomised controlled trials involving 2603 participants were included after screening 2446 records. Both prophylactic (MD = 0.17.95%CI: -0.06-0.4, p = 0.15) and therapeutic (MD = 0.03,95%CI: -0.18-0.23, p = 0.79) administration of norepinephrine showed no statistically significant difference in 1 min Apgar scores compared with phenylephrine. However, norepinephrine was associated with slightly higher 5 min Apgar scores during therapeutic administration compared with prophylactic administration (MD = 0.16,95% CI:0.01-0.31, p = 0.04). Norepinephrine revealed that no statistically significant difference in umbilical arterial partial carbon dioxide compared with phenylephrine when administered as bolus, infusion or combined bolus and infusion (MD = -0.98, 95%CI: -3.32-1.35, p = 0.41, MD = 0.43,95%CI: -0.54-1.4, p = 0.38 and MD = 0.25(-0.42-1.92) respectively. In contrast, norepinephrine significantly increased umbilical arterial bicarbonate level during therapeutic adminstration compared with prophylactic or combined prophylactic or therapeutic administration with phenylephrine (MD = 0.74,95%CI:0.15-1.33.p = 0.01). Regarding maternal outcomes,norepinephrine significantly reduced the risk of maternal bradycardia both in prophylactic (RR = 0.52,95%CI:0.34-0.78,p-0.02) and in therapeutic administratuin (RR = 0.46, 95%CI:0.29-0.72, p = 0.0006) compared with phenylephrine. Furthermore, pooled analysis showed that norepinephrine administration during combined of both prophylactic and therapeutic administration (RR = 0.29,95%CI:0.12-0.65, p = 0.003) was associated with lower risk of maternal reflex hypertension than during therapeutic and prophylactic alone compared with phenylephrine.ConclusionThis systematic review and meta-analysis shows women treated with bolus or infusion, prophylactic or therapeutic administration of norepinephrine have comparable neonatal outcome and maternal haemodynamics with phenylephrine. Therefore, Norepinephrine is an alternative vasopressor for management of spinal induced hypotension and for good neonatal outcome.
Abstract licence: CC BY
Babul A, Ashraf S, Desai J, et al.
2026
A. Habib
Anesthesia & Analgesia, 2012
Chao Xu, Su-fen Liu, Yizhou Huang, et al.
International journal of surgery, 2018
A. Doherty, Y. Ohashi, K. Downey, et al.
Anesthesia & Analgesia, 2012
M. Mohta, A. Garg, G. Chilkoti, et al.
Anaesthesia, 2019
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
5 minutes
Mechanism
Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction[A1…
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
38%
[A187379]
Clinically significant systemic absorption of ophthalmic formulations is possible, especially at higher strengths and when the cornea is damaged.
[L9416]
…
Half-life
5 minutes
[A187379][L9416][L9410]
Protein binding
[L9416][L9413][L9410]
Volume of distribution
340L
[L9416][L9410]
Metabolism
[A187382][A187385][L9416][L9410]
…
Elimination
86%
[L9416][L9410]
…
Clearance
2100mL/min
[L9416][L9410]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Phenylephrine was granted FDA approval in 1939.[L9413]
[L9416][L9410]
The ophthalmic formulation is indicated to induce mydriasis [L9413][L46332] and conjunctival vasoconstriction.
[A187370]
The intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids.
[A187370]
Off-label uses include priapism and induction of local vasoconstriction.
[A187370]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1018 interactions
[L9416][L9413][L9410]
Overdose may be treated by supportive care and discontinuing phenylephrine, chronotropic medications, and vasodilators.
[A187370]
Subcutaneous phentolamine may be used to treat tissue extravasation.
[A187370][L9413]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A187379]
Clinically significant systemic absorption of ophthalmic formulations is possible, especially at higher strengths and when the cornea is damaged.
[L9416]
[A187379][L9416][L9410]
[L9416][L9413][L9410]
[L9416][L9410]
[A187382][A187385][L9416][L9410]
The major metabolite is the inactive meta-hydroxymandelic acid, followed by sulfate conjugates.
[A187385][L9416][L9410]
Phenylephrine can also be metabolized to phenylephrine glucuronide.
[A187385]
[L9416][L9410]
[L9416][L9410]
Proteins and enzymes this drug interacts with in the body
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC S01FB01
ATC R01AB01
ATC C01CA06
ATC R01AA04
ATC C05AX06
ATC S01FB51
ATC S01GA05
ATC R01BA53
ATC S01GA55
ATC R01BA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Phenylephrine
Additional database identifiers
Drugs Product Database (DPD)
10258
Drugs Product Database (DPD)
6500
ChemSpider
5818
BindingDB
50067212
Guide to Pharmacology
485
ZINC
ZINC000000113355
HUGO Gene Nomenclature Committee (HGNC)
HGNC:277
GenAtlas
ADRA1A
GeneCards
ADRA1A
GenBank Gene Database
D25235
GenBank Protein Database
433201
Guide to Pharmacology
22
UniProt Accession
ADA1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:278
GenAtlas
ADRA1B
GeneCards
ADRA1B
GenBank Gene Database
M99589
Guide to Pharmacology
23
UniProt Accession
ADA1B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:280
GenAtlas
ADRA1D
GeneCards
ADRA1D
GenBank Gene Database
M76446
GenBank Protein Database
177807
Guide to Pharmacology
24
UniProt Accession
ADA1D_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3023
GenAtlas
DRD2
GeneCards
DRD2
GenBank Gene Database
M30625
GenBank Protein Database
181432
Guide to Pharmacology
215
UniProt Accession
DRD2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6833
GenAtlas
MAOA
GeneCards
MAOA
GenBank Gene Database
M68840
GenBank Protein Database
187353
Guide to Pharmacology
2489
UniProt Accession
AOFA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6834
GenAtlas
MAOB
GeneCards
MAOB
GenBank Gene Database
S62734
GenBank Protein Database
398415
Guide to Pharmacology
2490
UniProt Accession
AOFB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11455
GeneCards
SULT1A3
UniProt Accession
ST1A3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72